晚期肝癌的新标准护理疗法 — 与单独的靶向药物相比，立体

StephenW

晚期肝癌的新标准护理疗法
— 与单独的靶向药物相比，立体定向放射治疗加索拉非尼可提高生存率

作者：Charles Bankhead，今日 MedPage 高级编辑 2022 年 10 月 24 日

圣安东尼奥——根据这里报道的一项随机试验，在全身治疗中加入放射治疗可显着提高晚期肝癌的总生存期 (OS)。

中位 OS 从靶向药物索拉非尼 (Nexavar) 的 12.3 个月提高到立体定向放射治疗 (SBRT) 和索拉非尼的 15.8 个月。 6 到 24 个月的标志性生存分析都支持 SBRT 组，并且随着时间的推移，获益的幅度增加。

“在晚期肝细胞癌患者中，与单独使用索拉非尼相比，索拉非尼之前的 SBRT 改善了总生存期、无进展生存期 (PFS) 和进展时间 (TTP)，而不良事件没有增加，”Laura Dawson 报告说，多伦多玛格丽特公主癌症中心的医学博士在美国放射肿瘤学会 (ASTRO) 年会上。

StephenW

New Standard-of-Care Therapy for Advanced Liver Cancer
— Stereotactic body radiotherapy plus sorafenib improves survival versus targeted drug alone

by Charles Bankhead, Senior Editor, MedPage Today October 24, 2022

SAN ANTONIO -- Adding radiation therapy to systemic treatment significantly improved overall survival (OS) in advanced liver cancer, according to a randomized trial reported here.

Median OS improved from 12.3 months with the targeted drug sorafenib (Nexavar) to 15.8 months with stereotactic body radiation therapy (SBRT) followed by sorafenib. Landmark survival analyses from 6 to 24 months all favored the SBRT arm, and the magnitude of the benefit increased over time.

"In patients with advanced hepatocellular carcinoma, compared to sorafenib alone, SBRT prior to sorafenib improved overall survival, progression-free survival (PFS), and time to progression (TTP), without a concerning increase in adverse events," reported Laura Dawson, MD, of Princess Margaret Cancer Center in Toronto, at the American Society for Radiation Oncology (ASTRO) annual meeting.

StephenW

https://www.medpagetoday.com/mee ... al-gmail-definition

挚友888888

靶向和免疫治疗不起作用怎么办？靶向和免疫治疗只有30%人起作用，但是70%人应该怎么样治疗？还是不治疗也是一种治疗？